Persistance du traitement par inhibiteurs du facteur de nécrose tumorale et de l'IL-17 dans la spondylarthrite axiale : Analyse comparative multicentrique
Joint Bone Spine 2022; 89:105416 doi: 10.1016/j.jbspin.2022.105416
In this multi-centric, real-world study, persistence with secukinumab and TNFi were not statistically different for matched populations. The primary outcome of this analysis was drug persistence, calculated as the difference in months between initiation and discontinuation.